# Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

> **NCT00237198** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 47 (actual)

## Conditions studied

- Postmenopausal Women With Advanced Breast Cancer

## Interventions

- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT00237198
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2006-07
- **Final completion:** —
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2017-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00237198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00237198, "Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00237198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*